17 February 2021
Visongain has published a new report on Urothelial Cancer Drugs Market Report 2021-2031: Forecasts by Type (Urothelial Carcinoma, Squamous Cell Carcinoma, and Adenocarcinoma), by Treatment (Chemotherapy, Immunotherapy). PLUS Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Urothelial Cancer Drugs market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2031. The major aspects driving the market growth are the occurrence and attractiveness of directed therapy and rise in prevalence of urothelial cancer.
Urothelial carcinoma or transitional cell carcinoma is a malignant neoplasm arising from urothelium. The disease is the ninth most common malevolence in the world, with approximately 2.5 million patients and 420,000 newly identified cases each year. Bladder transitional cell carcinoma (TCC) recorded for approximately 90% of all urinary cancer cases.
COVID-19 Impact on Urothelial Cancer Drugs Market
The COVID-19 pandemic impact on the Urothelial Cancer Drugs Market growth is considered to be modest as the market is directly influenced by the spread of the urinary and kidney related disorders globally. The spread of pandemic is not making any negative impact on the growth of Urology Laser market.
The urothelial cancer drugs market is likely to be promoted from better therapies being approved by prominent drug regulatory organizations. Several innovative treatments are projected to see sanctions, further supporting the growth of the market during the analysis period.
The U.S. led the urothelial cancer drugs market in 2019, followed by Germany. The U.S. is estimated to retain its leading position during the forecast period, followed by Japan. Existence of a large target inhabitants, increased acceptance of innovative therapeutics, and forthcoming product launches during the forecast period will propel the market.
China exhibits a strong prospect for market expansion. Factors such as high unexploredmedical needs and the existence of a large target population are likely to boost the market in this region. Several domestic players are currently assessing products as second/third-line treatments in Phase II trials and are well-positioned to be launched in the China market in the future years.
According to the report published by World Cancer Research Fund International, Bladder cancer is the tenth most common cancer worldwide and there were almost 550,000 new cases in 2018. Lebanon is the country with the highest number of bladder cancers for the year 2019.
Some of the key players functioning in this market are Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Pfizer, Novartis AG, GlaxoSmithKline PLC, Sanofi SA, and Eisai Co. Ltd.
Merck and AstraZeneca are anticipated to lead the market during the forecast period, held by approvals of (Imfinzi + tremelimumab) and (Keytruda + chemotherapy) regimes in early lines of treatment for both chemo-ineligible and chemo-eligible patients. It is expected that immunity leveldefend therapy could replace the current customary of care in bladder cancer.Regional enlargement in evolving markets are key strategic activities of these companies to increase their market share. The market is expected to grow increasingly overcrowded with several product launches during the analysis period.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.
21 June 2022
The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.
20 June 2022
The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.
15 June 2022
The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.